SMMT
Summit Therapeutics Inc.NASDAQHealthcare$19.38+2.43%ClosedMarket Cap: $14.43B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
21.99
P/S
0.00
EV/EBITDA
-17.75
DCF Value
$0.34
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-296.8%
ROA
-144.1%
ROIC
-160.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-224.9M | $-219.2M | $-0.29 | — |
| FY 2025 | $0.00 | -Infinity% | $-1.09B | $-1.08B | $-1.44 | — |
| Q3 2025 | $0.00 | -Infinity% | $-234.2M | $-231.8M | $-0.31 | — |
| Q2 2025 | $0.00 | -Infinity% | $-568.4M | $-565.7M | $-0.76 | — |
| Q1 2025 | $0.00 | -Infinity% | $-66.9M | $-62.9M | $-0.09 | — |
| Q4 2024 | $0.00 | -Infinity% | $-65.6M | $-61.2M | $-0.08 | — |
| FY 2024 | $0.00 | -Infinity% | $-211.3M | $-221.3M | $-0.31 | — |
| Q3 2024 | $0.00 | -Infinity% | $-58.1M | $-56.3M | $-0.08 | — |
| Q2 2024 | $0.00 | -Infinity% | $-59.6M | $-60.4M | $-0.09 | — |
| Q1 2024 | $0.00 | -Infinity% | $-42.4M | $-43.5M | $-0.06 | — |
| Q4 2023 | $-235.0K | 357.4% | $-36.4M | $-36.6M | $-0.05 | — |
| FY 2023 | $0.00 | -Infinity% | $-89.7M | $-614.9M | $-0.99 | — |